Exor NV
Approval by AFM of Listing Prospectus
As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations, and as announced by Exor on 3 August 2022, the Company has received approval by the Euronext Listing Board of the admission to listing and trading of the Company’s ordinary shares on Euronext Amsterdam.
Approval by Euronext of admission to listing and trading
As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations.
Exor to transition its stock exchange listing to Euronext Amsterdam to align with the company’s dutch legal structure
SHARE BUYBACK TO CONTINUE WITH A SECOND TRANCHE OF UP TO €250 M
Exor (“Exor” or the “Company”) announces that its Board of Directors approved today the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, which hosts some of Europe’s leading corporations.
Agreement to acquire 10% of Institut Mérieux closed
Exor N.V. has closed today the agreement to acquire a 10% shareholding of Institut Mérieux, the privately held global healthcare holding of the Mérieux family. A consideration of €278 million, corresponding to one third of the €833 million total investment, was paid today by way of a reserved capital increase, while the remaining amount is expected to be contributed within the next 12 months.
As part of the partnership sealed with the Mérieux family, John Elkann and Benoît Ribadeau-Dumas have joined Institut Mérieux’s Board of Directors.
Exor completes the sale of PartnerRe to Covéa for a total cash consideration of $9.3 billion (€8.6 billion)
Exor announces that it has completed the sale of PartnerRe, the global reinsurer, to Covéa for a total cash consideration of $9.3 billion (approximately €8.6 billion1). This is based on a consolidated common shareholders’ equity value of $7.3 billion as at 31 December 2021.
The acquisition of PartnerRe by Covéa reinforces PartnerRe’s development as a great company in its industry thanks to a significant increase in the scale and capital strength that membership of a larger financial institution brings, and the value that it represents for its clients.